877069-25-5 Usage
Uses
Used in Medicinal Chemistry:
(2S,4R)-1-((S)-2-(cyclopentyloxycarbonyl)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxylic acid is used as a pharmaceutical intermediate for the development of new drugs. Its unique structure and functional groups may provide specific biological activities, making it a promising candidate for the treatment of various diseases.
Used in Synthesis of Complex Molecules:
(2S,4R)-1-((S)-2-(cyclopentyloxycarbonyl)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxylic acid is used as a building block in the synthesis of more complex organic molecules. Its versatile structure allows for further functionalization and modification, enabling the creation of novel compounds with potential applications in various fields.
Used in Pharmaceutical Industry:
(2S,4R)-1-((S)-2-(cyclopentyloxycarbonyl)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxylic acid is used as a key component in the development of innovative pharmaceuticals. Its unique stereochemistry and functional groups may contribute to the design of drugs with improved efficacy, selectivity, and reduced side effects.
Used in Chemical Research:
(2S,4R)-1-((S)-2-(cyclopentyloxycarbonyl)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxylic acid is used as a subject of study in chemical research to explore its properties, reactivity, and potential applications. Understanding its behavior in various chemical reactions can provide insights into the development of new synthetic methods and applications in different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 877069-25-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,7,0,6 and 9 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 877069-25:
(8*8)+(7*7)+(6*7)+(5*0)+(4*6)+(3*9)+(2*2)+(1*5)=215
215 % 10 = 5
So 877069-25-5 is a valid CAS Registry Number.
877069-25-5Relevant academic research and scientific papers
PAT application in the expedited development of a three-step, one-stage synthesis of the dipeptide intermediate of HCV protease inhibitor faldaprevir
Haddad, Nizar,Qu, Bo,Lee, Heewon,Lorenz, Jon,Varsolona, Rich,Kapadia, Suresh,Sarvestani, Max,Feng, XuWu,Busacca, Carl A.,Hebrault, Dominique,Rea, Simon,Schellekens, Leen,Senanayake, Chris H.
, p. 132 - 138 (2015/03/03)
A concise scalable synthesis of a chiral dipeptide acid, key substructure of the HCV protease inhibitor faldaprevir, has been developed. A green process with an E-factor of 9.2 was achieved utilizing process analytical technology (PAT) to allow effective processing of multiple-steps in a one-stage operation. Mixed anhydride/oxazolone formation, peptide coupling, saponification, and then crystallization of the desired dipeptide acid were completed within 10 h. MultiMaxIR was used to detect the formation and consumption rates of key intermediates and to provide initial safety data which was subsequently confirmed by more comprehensive process safety testing. Further kinetic analysis was performed to determine the range of operability space to ensure conditions for a robust process.
CRYSTALLINE FORMS OF A 2-THIAZOLYL- 4-QUINOLINYL-OXY DERIVATIVE, A POTENT HCV INHIBITOR
-
Page/Page column 24-25, (2010/04/25)
This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection.
ANTIVIRAL COMPOUNDS
-
Page/Page column 319-320, (2008/06/13)
The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
